Skip to main content

Von Willebrand Disease

9
Pipeline Programs
8
Companies
20
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
5
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

CSL Seqirus
CSL SeqirusUK - Maidenhead
10 programs
1
2
2
Blood coagulation Factor VIII and vWF, humanPhase 4
VoncentoPhase 4
BiostatePhase 3
BiostatePhase 3
Biostate®Phase 2/3
+5 more programs
Biocorp
BiocorpFrance - Issoire
3 programs
3
OptivatePhase 31 trial
OptivatePhase 31 trial
Optivate®Phase 31 trial
Active Trials
NCT00387192Terminated26Est. Sep 2008
NCT00404300Terminated25Est. Sep 2008
NCT02246881Completed
Pfizer
PfizerNEW YORK, NY
1 program
1
recombinant interleukin-11Phase 21 trial
Active Trials
NCT00151125Completed12Est. Dec 2007
CSL Behring
CSL BehringIL - Bradley
10 programs
A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)N/A1 trial
National Study of Moderate and Severe Von Willebrand Disease in the NetherlandsN/A1 trial
VWF/FVIII productsN/A1 trial
Von Willebrand Disease in the NetherlandsN/A1 trial
Voncento®N/A1 trial
+5 more programs
Active Trials
NCT00701545Completed21Est. Apr 2009
NCT00510042Completed1,100Est. Sep 2009
NCT00557908Completed105Est. Feb 2013
+5 more trials
Octapharma
OctapharmaAustria - Vienna
2 programs
Patients using Wilate as standard of careN/A1 trial
WilatePHASE_31 trial
Active Trials
NCT01602419Completed120Est. Apr 2018
NCT04953884Completed12Est. Dec 2024
Takeda
TakedaTOKYO, Japan
2 programs
Recombinant von Willebrand factor : recombinant FVIIIPHASE_11 trial
Recombinant von Willebrand FactorPHASE_31 trial
Active Trials
NCT00816660Completed32Est. Aug 2010
NCT02283268Completed24Est. Jul 2016
Parexel
ParexelMA - Boston
2 programs
Biostate®PHASE_2_31 trial
BiostatePHASE_31 trial
Active Trials
NCT00941616Completed22Est. Feb 2012
NCT01213446Completed17Est. Aug 2013
Grifols
GrifolsNEW YORK, NY
2 programs
Alphanate SD/HTPHASE_41 trial
plasma-derived FVIII/VWF concentratePHASE_41 trial
Active Trials
NCT00555555Terminated4Est. Feb 2012
NCT02472665Withdrawn0Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CSL BehringVoncento
Grifolsplasma-derived FVIII/VWF concentrate
GrifolsAlphanate SD/HT
CSL BehringBlood coagulation Factor VIII and vWF, human
OctapharmaWilate
TakedaRecombinant von Willebrand Factor
CSL BehringBiostate
ParexelBiostate
BiocorpOptivate
BiocorpOptivate
BiocorpOptivate®
ParexelBiostate®
Pfizerrecombinant interleukin-11
TakedaRecombinant von Willebrand factor : recombinant FVIII
CSL BehringVon Willebrand Disease in the Netherlands

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 2,831 patients across 20 trials

NCT02552576CSL BehringVoncento

Study of Voncento® in Subjects With Von Willebrand Disease

Start: Oct 2015Est. completion: Feb 201826 patients
Phase 4Completed
NCT02472665Grifolsplasma-derived FVIII/VWF concentrate

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease

Start: Dec 2013Est. completion: Dec 20240
Phase 4Withdrawn
NCT00555555GrifolsAlphanate SD/HT

Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

Start: Jul 2008Est. completion: Feb 20124 patients
Phase 4Terminated
NCT00168090CSL BehringBlood coagulation Factor VIII and vWF, human

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

Start: Oct 2001Est. completion: May 200630 patients
Phase 4Completed
NCT04953884OctapharmaWilate

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

Start: Sep 2021Est. completion: Dec 202412 patients
Phase 3Completed
NCT02283268TakedaRecombinant von Willebrand Factor

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

Start: Apr 2015Est. completion: Jul 201624 patients
Phase 3Completed
NCT01224808CSL BehringBiostate

Extension Study of Biostate in Subjects With Von Willebrand Disease

Start: Oct 2010Est. completion: Mar 201420 patients
Phase 3Completed
NCT01213446ParexelBiostate

Study of Biostate® in Children With Von Willebrand Disease

Start: Aug 2010Est. completion: Aug 201317 patients
Phase 3Completed
NCT00404300BiocorpOptivate

Optivate in People With Von Willebrand Disease Undergoing Surgery

Start: Feb 2007Est. completion: Sep 200825 patients
Phase 3Terminated
NCT00387192BiocorpOptivate

A Study With OPTIVATE® in People With Von Willebrand Disease

Start: Nov 2006Est. completion: Sep 200826 patients
Phase 3Terminated
NCT02246881BiocorpOptivate®

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Start: Oct 2001
Phase 3Completed
NCT00941616ParexelBiostate®

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Start: Jun 2009Est. completion: Feb 201222 patients
Phase 2/3Completed
NCT00151125Pfizerrecombinant interleukin-11

Phase II Study of IL-11 (Neumega) in Von Willebrand Disease

Start: Jul 2004Est. completion: Dec 200712 patients
Phase 2Completed
NCT00816660TakedaRecombinant von Willebrand factor : recombinant FVIII

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Start: Dec 2008Est. completion: Aug 201032 patients
Phase 1Completed
NCT03521583CSL BehringVon Willebrand Disease in the Netherlands

Von Willebrand Disease in the Netherlands

Start: Jul 2019Est. completion: Jan 20221,100 patients
N/AUnknown
NCT04657887CSL BehringVoncento®

Registry of Patients With Von WilLEbrand Disease Treated With Voncento®

Start: Nov 2015Est. completion: Dec 2023135 patients
N/ACompleted
NCT01602419OctapharmaPatients using Wilate as standard of care

Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

Start: Oct 2012Est. completion: Apr 2018120 patients
N/ACompleted
NCT00701545CSL BehringA Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

Start: Feb 2008Est. completion: Apr 200921 patients
N/ACompleted
NCT00510042CSL BehringNational Study of Moderate and Severe Von Willebrand Disease in the Netherlands

National Study of Moderate and Severe Von Willebrand Disease in the Netherlands

Start: Jul 2007Est. completion: Sep 20091,100 patients
N/ACompleted
NCT00557908CSL BehringVWF/FVIII products

The Von Willebrand Disease (VWD) International Prophylaxis Study

Start: Jun 2007Est. completion: Feb 2013105 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.